Jose Lutzky on Proactively Monitoring Patients Receiving Immunotherapy Treatments
Jose Lutzky, MD, discusses the importance of proactive patient monitoring with patients receiving immunotherapy treatments.
Jose Lutzky, MD, from Mount Sinai Medical Center, discusses the best practices for monitoring patients on immunotherapy.
With treatments that are potentially very toxic, it is important to develop a plan for following up with the patients. Every patient is different and some will need closer monitoring than others. Nurses shouldn’t rely on the patient to reach out to them, either. For treatments that could possibly result in these kinds of adverse events, it is better to take a more proactive approach to patient monitoring.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
